Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: A randomized controlled trial

AIDS

Volumn 23, Issue 2, 2009, Pages 203-212

  Porter, Brian O ^a   Anthony, Kara B ^a   Shen, Jean ^b   Hahn, Barbara ^b   Keh, Chris E ^a   Maldarelli, Frank ^c   Blackwelder, William C ^a   Lane, Henry Clifford ^a   Kovacs, Joseph A ^d   Davey, Richard T ^a   Sereti, Irini ^a,e  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Critical Care Medicine Department   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CD4 lymphocyte count; HAART; HIV infections; Interleukin 2; Lipodystrophy; Randomized controlled trial

Indexed keywords

ANTIRETROVIRUS AGENT; GLYCOSYLATED HEMOGLOBIN; RECOMBINANT INTERLEUKIN 2; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; FEVER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; IMMUNE RESPONSE; KAPOSI SARCOMA; LIPODYSTROPHY; LIVER TOXICITY; MALE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SECONDARY SYPHILIS; THERAPY DELAY; TREATMENT OUTCOME; VIRUS LOAD;

ADULT; AGED; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; T-LYMPHOCYTE SUBSETS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 58849148911     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32831cc114     Document Type: Article

References (62)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853-860.
2. Ledergerber B, Egger M, Telenti A. AIDS-related opportunistic illness and potent antiretroviral therapy. JAMA 2000; 283: 2653-2654.
3. Mocroft A, VeIIa S, Benfield TL, Chiesi A, Miller V, Gargalianos P, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352: 1725-1730.
4. Ofotokun I, Smithson SE, Lu C, Easley KA, Lennox JL. Liver enzymes elevation and immune reconstitution among treatment-naive HIV-infected patients instituting antiretroviral therapy. Am I Med Sci 2007; 334:334-341.
5. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005; 352:48-62.
6. Grinspoon SK. Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am j Med 2005; 118 (Suppl 2):23S-28S.
7. Maggiolo F, Ripamonti D, Gregis G, Quinzan G, Callegaro A, Suter F. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4 T cells: a controlled, prospective trial. AIDS 2004; 18:439-446.
8. Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368:459-165.
9. Ananworanich J, Nuesch R, Le Braz M, Chetchotisakd P, Vib- hagool A, Wicharuk S, et al. Failures of 1 week on, 1 week off antiretroviral therapies in a randomized trial. AIDS 2003; 17:F33-F37.
10. Danei C, Moh R, Minga A, Anzian A, Ba-Gomis O, Kanga C, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981 1989.
11. El-Sadr WM, Lundgren JD, Neaton JD, Gordin F, Abrams D, Arduino RC, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
12. Silverberg MJ, Neuhaus J, Bower M, Gey D, Hatzakis A, Henry K, et al. Risk of cancers during interrupted antiretroviral therapy in the SMART study. AIDS 2007; 21 : 1957-1963.
13. Arduino RC, Nannini EC, Rodriguez-Barradas M, Schrader S, Losso M, Ruxrungtham K, et al. CD4 cell response to 3 doses of subcutaneous interleukin 2: meta-analysis of 3 Vanguard studies. Clin Infect Dis 2004; 39: 115-122.
14. Farel CE, Chaitt DG, Hahn BK, Tavel JA, Kovacs J A, Polis MA, et al. Induction and maintenance therapy with intermittent interleukin-2 in HIV-1 infection. Blood 2004; 103:3282- 3286.
15. Natarajan V, Lempicki RA, Sereti I, Badralmaa Y, Adelsberger JW, Metcalf JA, et al. Increased peripheral expansion of naive CD4+ T cells in vivo after IL-2 treatment of patients with HIV infection. Proc Natl Acad Sci USA 2002; 99: 10712- 10717.
16. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Sereti I, Sachau W, et al. Induction of prolonged survival of CD4+- T lymphocytes by intermittent IL-2 therapy in HIV-infected patients. J Clin Invest 2005; 115:2139-2148.
17. Sereti I, Anthony KB, Martinez-Wilson H, Lempicki R, Adelsberger J, Metcalf JA, et al. IL-2-induced CD4+ T-cell expansion in HIV-infected patients is associated with long-term decreases in T-cell proliferation. Blood 2004; 104:775-780.
18. Kovacs JA, Vogel S, Metcalf JA, Baseler M, Stevens R, Adelsberger J, et al. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy. Eur j Immunol 2001; 31: 1351-1360.
19. Sereti I, Imamichi H, Natarajan V, Imamichi T, Ramchandani MS, Badralmaa Y, et al. In vivo expansion of CD4(+)CD45RO(-)CD25(+) T cells expressing foxP3 in IL- 2-treated HIV-infected patients. J Clin Invest 2005; 115: 1839- 1847.
20. Sereti I, Martinez-Wilson H, Metcalf JA, Baseler MW, Hallahan CW, Hahn B, et al. Long-term effects of intermittent interleukin 2 therapy in patients with HIV infection: characterization of a novel subset of CD4(+)/CD25(+) T cells. Blood 2002, 100:2159-2167.
21. Pett SL, Wand H, Law MG, Arduino R, Lopez JC, Knysz B, et al. Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial (ESPRIT): geographical and gender differences in the baseline characteristics of participants. HIV Clin Trials 2006; 7:70-85.
22. Emery S, Abrams DI, Cooper DA, Darbyshire JH, Lane HC, Lundgren JD, Neaton JD. The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT. Control Clin Trials 2002; 23: 198-220.
23. Durier C, Capitant C, Lascaux AS, Goujard C, Oksenhendler E, Poizot-Martin I, et al. Long-term effects of intermittent inter- Ieukin-2 therapy in chronic HIV-infected patients (ANRS 048- 079 Trials). AIDS 2007; 21 : 1887-1897.
24. Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux AS, et al. Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS 2003; 17:343- 351.
25. Davey RT Jr, Murphy RL, Graziano FM, Boswell SL, Pavia AT, Cancio M, et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: a randomized controlled trial. JAMA 2000; 284: 183-189.
26. Levy Y, Gahery-Segard H, Durier C, Lascaux AS, Goujard C, Meiffredy V, et al. Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 2005; 19:279-286.
27. KiIby JM, Bucy RP, Mildvan D, FischI M, Santana-Bagur J, Lennox J, et al. A randomized, partially blinded phase 2 trial of antiretroviral therapy, HIV-specific immunizations, and interleukin-2 cycles to promote efficient control of viral replication (ACTG A5024). J Infect Dis 2006; 194: 1672-1676.
28. Henry K, Katzenstein D, Cherng DW, Valdez H, Powderly W, Vargas MB, et al. A pilot study evaluating time to CD4 T-cell count <350 cells/mm(3) after treatment interruption following antiretroviral therapy ± interleukin 2: results of ACTG A5 102.J Acquir Immune Defic Syndr 2006; 42: 140-148.
29. Keh CE, Shen JM, Hahn B, Hallahan CW, Rehm CA, Thaker V, et al. Interruption of antiretroviral therapy blunts but does not abrogate CD4 T-cell responses to interleukin-2 administration in HIV infected patients. AIDS 2006; 20:361-369.
30. YouIe M, Emery S, Fisher M, Nelson M, Fosdick L, Janossy G, et al. A Randomised Trial of Subcutaneous Intermittent Interleukin-2 without Antiretroviral Therapy in HIV-infected Patients: the UK-Vanguard Study. PLoS Clin Trials 2006; 1 :e3.
31. Kovacs J A, Baseler M, Dewar RJ, VogeI S, Davey RT Jr, FaIIoon J, et al. Increases in CD4 T lymphocytes with intermittent courses of interleukin-2 in patients with human immunodeficiency virus infection. A preliminary study. N Engl J Med 1995; 332:567-575.
32. Davey RT Jr, Chaitt DG, Piscitelli SC, Wells M, Kovacs JA, Walker RE, et al. Subcutaneous administration of interleukin-2 in human immunodeficiency virus type 1-infected persons. J Infect Dis 1997; 175:781-789.
33. Zhang H, Chua KS, Guimond M, Kapoor V, Brown MV, Fleisher TA, et al. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005; 11:1238-1243.
34. Stevens R, Lempicki R, Natarajan V, Higgins J, Adelsberger J, Metcalfe J. General immunologic evaluation of patients with human immunodeficiency virus infection. In: Manual of molecular and clinical laboratory immunology, 7th ed. Edited by Detrick B, Folds RHJJ.Washington, DC: ASM Press; 2006. pp. 847-861.
35. Ellis KJ, Grund B, Visnegarwala F, Thackeray L, Miller CG, Chesson CE, et al. Visceral and subcutaneous adiposity measurements in adults: influence of measurement site. Obesity (Silver Spring) 2007; 15:1441-1447.
36. Volberding PA, Lagakos SW, Koch MA, Pettinelli C, Myers MW, Booth DK, et al. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases. N Engl J Med 1990; 322:941-949.
37. Wu AW, Revicki DA, Jacobson D, MaIitz FE. Evidence for reliability, validity and usefulness of the Medical Outcomes Study HIV Health Survey (MOS-HIV). Qual Life Res 1997; 6:481-493.
38. Safrin S, Finkelstein DM, Feinberg J, Frame P, Simpson G, Wu A, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996; 124:792-802.
39. Gart JJ, Nam JM. Approximate interval estimation of the difference in binomial parameters: correction for skewness and extension to multiple tables. Biometrics 1990; 46:637-643.
40. Davey RT Jr, Chaitt DG, Albert JM, Piscitelli SC, Kovacs JA, Walker RE, et al. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J Infect Dis 1999; 179:849-858.
41. http://hivdb.stanford.edu/. Stanford University HIV Drug Resistance Database. 2008.
42. Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey J, Reich- man R, et al. The virologic, immunologic, and clinical effects of interleukin 2 with potent antiretroviral therapy in patients with moderately advanced human immunodeficiency virus infection: a randomized controlled clinical trial - AIDS Clinical Trials Group 328. Arch Intern Med 2007; 167 :597-605.
43. Di Mascio M, Sereti I, Matthews LT, Natarajan V, Adelsberger J, Lempicki R, et al. Naive T-cell dynamics in human immunodeficiency virus type 1 infection: effects of highly active antiretroviral therapy provide insights into the mechanisms of naive T-cell depletion. J Virol 2006, 80:2665-2674.
44. Anthony KB, Yoder C, Metcalf JA, DerSimonian R, Orenstein JM, Stevens RA, et al. Incomplete CD4 T cell recovery in HIV-1 infection after 12 months of highly active antiretroviral therapy is associated with ongoing increased CD4 T cell activation and turnover. J Acquir Immune Defic Syndr 2003; 33: 125-133.
45. Hunt PW, Brenchley J, Sinclair E, McCuneJM, Roland M, Page- Shafer K, et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126-133.
46. Kovacs JA, Lempicki RA, Sidorov IA, Adelsberger JW, Herpin B, Metcalf JA, et al. Identification of dynamically distinct sub- populations of T lymphocytes that are differentially affected by HIV. J Exp Med 2001; 194:1731-1741.
47. Sereti I, Lane HC. Immunopathogenesis of human immunodeficiency virus: implications for immune-based therapies. Clin Infect Dis 2001; 32:1 738-1 755.
48. Rodriguez B, Sethi AK, Cheruvu VK, Mackay W, Bosch RJ, Kitahata M, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA 2006; 296:1498-1506.
49. Mellors JW, Margolick JB, Phair JP, Rinaldo CR, Detels R, Jacobson LP, Munoz A. Prognostic value of HIV-1 RNA, CD4 cell count, and CD4 cell count slope for progression to AIDS and death in untreated HIV-1 infection. JAMA 2007; 297:2349-2350.
50. Goujard C, Marcellin F, Hendel-Chavez H, Burgard M, Meif- fredy V, Venet A, et al. Interruption of antiretroviral therapy initiated during primary HIV-1 infection: impact of a therapeutic vaccination strategy combined with interleukin (IL)-2 compared with IL-2 alone in the ANRS 095 Randomized Study. AIDS Res Hum Retroviruses 2007; 23: 1105- 1113.
51. Angus B, Lampe F, Tambussi G, Duvivier C, Katlama C, Youle M, et al. TILT: a randomized controlled trial of interruption of antiretroviral therapy with or without interleukin-2 in HIV-1 infected individuals. AIDS 2008; 22:737-740.
52. Fox Z, Antunes F, Davey R, Gazzard B, KIimas N, Labriola A, et al. Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count ≥ or =300cells/microL who were assigned to 7.5 MIL) interleukin-2. HIV Med 2007; 8:112-123.
53. Markowitz N, Bebchuk JD, Abrams DI. Nadir CD4+ T cell count predicts response to subcutaneous recombinant interleukin-2. Clin Infect Dis 2003; 37:e 115-e 120.
54. Read SW, Lempicki RA, Mascio MD, Srinivasula S, Burke R, Sachau W, et al. CD4 T cell survival after intermittent interleukin-2 therapy is predictive of an increase in the CD4 T cell count of HIV-infected patients. J Infect Dis 2008; 198:843-850.
55. Davey RT Jr, Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 1999; 96:15109-15114.
56. Ruiz L, Paredes R, Gomez G, Romeu J, Domingo P, Perez- Alvarez N, et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS 2007; 21 : 169-178.
57. Tarwater PM, Parish M, Gallant JE. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. Clin Infect Dis 2003; 37: 1541-1548.
58. Tebas P, Henry WK, Matining R, Weng-Cherng D, Schmitz, Valdez H, et al. Metabolic and immune activation effects of treatment interruption in chronic HIV-1 infection: implications for cardiovascular risk. PLoS ONE 2008; 3:e2021.
59. Diop ME, Bastard JP, Meunier N, Thevenet S, Maachi M, Capeau), et al. Inappropriately low glycated hemoglobin values and hemolysis in HIV-infected patients. AIDS Res Hum Retroviruses 2006; 22: 1242- 1247.
60. Emery S, Neuhaus J, Phillips A, Babiker A, Cohen CJ, Gatell J, et al. Major clinical outcomes in antiretroviral therapy (ART)- naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis 2008; 197:000-10.
61. http://www3.niaid.nih.gov/healthscience/clinicalstudies/ HIVandlnfectious/HIVstudies/STALWART.htm. NIAID HIV and Emerging Infectious Diseases Program: STALWART Study; 2008.
62. Molina J LY, Fournier I, Boulet T, Bentata M, Beck-Wirth G, Sereni D, et al. Predictors of slow disease progression in antiretroviral (ART) naive HIV-1 infected patients treated with IL-2: three-year extended follow-up of the Interstart ANRS 119 trial. In: 15th Conference on Retroviruses and Opportunistic Infections; Boston, Massachusetts; 2008.